Physician profile
William James Blanke
NPI 1720048754
$270.99
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $225 · 2021: $31.99 · 2022: $14.34.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $57.49 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $46.56 | 2019 | |
| Abbvie INC. | $46.33 | 2021-2022 | |
| Neos Therapeutics, LP | $21.04 | 2019 | |
| Duchesnay USA Incorporated | $18.82 | 2019 | |
| Lilly USA, LLC | $15.50 | 2019 | |
| Eisai INC. | $15.43 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.58 | 2019 | |
| Glaxosmithkline, LLC. | $12.28 | 2019 | |
| Novo Nordisk INC | $12.02 | 2019 | |
| Avanir Pharmaceuticals, INC. | $10.94 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Blanke listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.